
Letters: How reforming California rooftop solar policies will benefit all the state's residents
Regarding 'California wants to kill rooftop solar — all because officials were duped by this flawed theory' (Open Forum, SFChronicle.com, May 11): The op-ed downplaying the rooftop solar cost shift is misleading and ignores overwhelming evidence.
The California Public Advocates Office found that nonsolar customers paid $8.5 billion in 2024 alone to subsidize rooftop solar users — making up as much as 27% of their electricity bills. That's not theory; it's math.
The author leans on a study by his firm, M.Cubed, that's been debunked. UC Berkeley energy economist Severin Borenstein called it out for 'fundamental conceptual errors' and 'misunderstanding how customers contribute to fixed grid costs.'
Even California Public Utilities Commission-approved modeling shows that net-energy-metering customers cover as little as 9% to 18% of the actual cost to serve them.
Fixing the cost shift doesn't mean abandoning solar — it means creating a system that is fair to everyone, not just the 1.6 million households with panels. Working-class Californians shouldn't pay billions so wealthier homeowners can enjoy near-zero electric bills.
Environment can't be rebuilt
Regarding 'California blocking new housing in this posh Silicon Valley town over wildflowers' (Bay Area, SFChronicle.com, May 10): The Peninsula's rare serpentine meadows and wildflower-rich grasslands are more than just scenic — they're essential lifelines in a time of climate change and biodiversity collapse.
The story frames the issue as wildflowers versus housing, but this is a dangerous oversimplification. These ecosystems support a rich tapestry of endemic and endangered species that exist nowhere else. Destroying them for short-term development is not just shortsighted — it's irreversible.
We urgently need affordable housing, but not at the expense of irreplaceable biodiversity. Nature-based climate solutions rely on protecting intact ecosystems like these meadows, which store carbon, support pollinators and build resilience against climate shocks.
Let's prioritize smart development rather than paving over the last fragments of ecological heritage. Preserving biodiversity isn't a luxury — it's a necessity for a livable future.
Bob Hall, San Francisco
Limit coyote killing
As the saying goes, crazy is doing the same thing over and over but expecting different results.
By this measure, coyote management in California and nationwide has been crazy for decades, with constant, indiscriminate killing and taxpayer-funded extermination programs — all while coyotes survive and move into new areas.
Fortunately, California is poised for change. The California Fish and Game Commission's Wildlife Resources Committee will consider new rules to limit coyote killing.
Science demonstrates that intense persecution of coyotes increases conflicts by encouraging more reproduction and opening territories to inexperienced, juvenile dispersers prone to seek food like garbage and small pets.
Nonlethal methods: hazing, livestock fencing, keeping pets on leash and garbage secured have proven more effective in reducing human-coyote conflicts.
Wildlife Resources Committee's recommendation must be adopted so that the state can advance new approaches to coyote management and coexistence, which in these changing times are both very necessary and very sane.
Camilla Fox, executive director, Project Coyote, Larkspur
Doesn't seem right
Is anyone else worried about this extravagant gift to President Donald Trump from Qatar? Isn't Air Force One considered the Oval Office when the president travels? To quote Han Solo: 'I have a bad feeling about this.'
Arlene DeLeon, Castro Valley
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Highridge Medical Completes the Sale of its Bone Healing Division to Streamline Strategic Focus and Innovation in Spine
Sale proceeds will accelerate investment in portfolio innovation and commercial expansion for Spine. WESTMINSTER, Colo., June 04, 2025 (GLOBE NEWSWIRE) -- Highridge Medical ('Highridge' or the 'Company'), one of the world's largest privately held Spine companies, has completed the sale of EBI, its Bone Healing division, to Avista Healthcare Partners. The transaction aligns with the Company's strategy to exclusively focus on Spine and drive long-term growth through dedicated investment in innovation and expansion of commercial capabilities. Highridge will use the proceeds to accelerate investment in portfolio innovation and commercial expansion. The Bone Healing division, which specializes in non-invasive and implantable, FDA-approved, bone growth stimulation therapies for spine, orthopedics, and podiatric patients will now operate as an independent company backed by Avista Healthcare Partners. 'Divesting the Bone Healing division allows Highridge to further sharpen our focus on our most promising growth opportunities. We are committed to driving innovation in partnership with our surgeon customers to deliver innovative spinal solutions to enhance patient outcomes,' said Rebecca Whitney, Chief Executive Officer of Highridge Medical. 'We would like to thank the dedicated EBI team and are confident that they will thrive as they continue to focus on innovation and advancing patient care.' About Highridge Medical Highridge Medical is a global medical device company committed to improving spine care by partnering with the surgeon community to drive innovation. The company has a strong portfolio supported by extensive clinical evidence including solutions for complex spine, motion preservation, and minimally invasive surgery. For further information, please visit Media Contact: Mark Richards(512) in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
In National Advertising Division Challenge, Bayview Pharmacy Voluntarily Discontinues Claims for its Compounded Semaglutide
BBB National Programs' National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and implied advertising claims made by Bayview Pharmacy Inc. for its compounded semaglutide products. New York, NY, June 04, 2025 (GLOBE NEWSWIRE) -- BBB National Programs' National Advertising Division reviewed a challenge brought by Novo Nordisk Inc. regarding express and implied advertising claims made by Bayview Pharmacy Inc. for its compounded semaglutide products. Novo Nordisk is a global pharmaceutical company specializing in diabetes care, including insulin and related products, as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk is the sole manufacturer of the only FDA-approved semaglutide medicines: Ozempic® and Wegovy®. Bayview, a compounding pharmacy, marketed five concentrations of compounded semaglutide product for sublingual application for blood-sugar control and weight loss on its website. Novo Nordisk argued that Bayview's advertising conveyed misleading messages, including that its compounded 'semaglutide' sublingual suspensions are Ozempic® and/or is the same as a generic version of Ozempic®. In addition, Novo Nordisk argued that Bayview makes several misleading superiority claims about the bioavailability of its compounded semaglutide sublingual suspension. During the inquiry, Bayview informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued. In its advertiser statement, Bayview stated it 'will comply with NAD's recommendations' and that it 'appreciates NAD's guidance.' All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes. About BBB National Programs: BBB National Programs, a non-profit organization, is the home of U.S. independent industry self-regulation, currently operating more than 20 globally recognized programs that have been helping enhance consumer trust in business for more than 50 years. These programs provide third-party accountability and dispute resolution services that address existing and emerging industry issues, create fair competition for businesses, and a better experience for consumers. BBB National Programs continues to evolve its work and grow its impact by providing business guidance and fostering best practices in arenas such as advertising, child-and-teen-directed marketing, data privacy, dispute resolution, automobile warranty, technology, and emerging areas. To learn more, visit About the National Advertising Division: The National Advertising Division (NAD) of BBB National Programs provides independent self-regulation and dispute resolution services, guiding the truthfulness of advertising across the U.S. NAD reviews national advertising in all media and its decisions set consistent standards for advertising truth and accuracy, delivering meaningful protection to consumers and create fair competition for business. CONTACT: Name: Jennie Rosenberg Email: jrosenberg@ Job Title: Media RelationsSign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
MemorialCare Heart & Vascular Institute Completes First Successful TriClip Procedure for Tricuspid Valve Repair
LONG BEACH, Calif., June 4, 2025 /PRNewswire/ -- The cardiology team at the MemorialCare Heart & Vascular Institute at Long Beach Medical Center, led by Chief of Cardiology David Shavelle, M.D., performed Long Beach Medical Center's first transcatheter tricuspid valve replacement procedure using a new, innovative treatment option – the transcatheter edge-to edge repair (TEER) TriClip G4 System in September of 2024. The FDA-approved TriClip is a small clipping device designed to clip two or more of the leaflets of the tricuspid, offering a minimally invasive treatment option to patients who have tricuspid regurgitation (TR) – a condition where the tricuspid valve does not close completely when the right ventricle contracts. This device – implanted via a catheter inserted in the vein of the leg – helps reduce tricuspid regurgitation and promotes an immediate improvement in blood flow and allows patients to benefit from a less traumatic procedure and a faster recovery. This advanced technology marks a new era for treating tricuspid valve disease since prior to its introduction, patients could only receive a device better suited for the mitral valve (MitraClip® device). The TriClip device was specifically made for the tricuspid valve. In a large clinical trial, the device was shown to reduce symptoms and hospitalization for heart failure for patients at high-risk for open-heart surgery. "This new procedure represents a significant advancement in our ability to treat high-risk patients with tricuspid valve heart disease," says Dr. Shavelle, who led the landmark procedure. "Historically there wasn't much we could do for those who still had symptoms after tricuspid regurgitation treatment and who were at high-risk for open heart surgery. This device gives patients access to improved quality of life." This procedure was performed by a highly skilled, diverse team of cardiologists, cardiac surgeons, cardiac anesthesiologists and advanced imaging specialists from the MemorialCare Heart & Vascular Institute at Long Beach Medical Center. Implantation of the TriClip with the TriClip G4 System is as effective as open-heart surgery, helping patients return to their daily lives in one to two days. "The patient recovered in the hospital for about two days, and he was able to return to his daily life the following day," says Dr. Shavelle. "It's amazing to see the positive impact this device has on our patients, allowing them to return to their daily lives with improved heart function and overall well-being." The patient who received this procedure, Anthony Williams, reported being fatigued constantly with excessive swelling of the legs (edema) before the procedure. Today, he is more energetic than ever and ready to take on each day. MemorialCare Heart & Vascular Institute at Long Beach Medical Center is the first institute in the region to use this device and continues to lead in cardiovascular innovations, bringing patients with the latest technology advancements. As one of the most high performing hospitals according to U.S. News, MemorialCare Long Beach Medical Center is a six-time five-star recipient recognized for its excellence in cardiac care by Healthgrades, and has recently received the American Heart Association's Get With The Guidelines® Heart Failure Gold Plus Quality Achievement Award, as well as the American Heart Association/American Stroke Association's Get With The Guidelines® Stroke Gold Plus Quality Achievement Award. With these achievements and offering a comprehensive range of services for patients with cardiac disorders, including rehabilitation programs, Long Beach Medical Center is a community hospital dedicated in providing expert and compassionate care on par with those found in academic settings. About MemorialCare Long Beach Medical Center: MemorialCare Long Beach Medical Center is a member of MemorialCare, a not-for-profit, integrated healthcare system. Long Beach Medical Center has been providing the community with compassionate, quality health care for more than 100 years. At the forefront of specialized care, research, and education, Long Beach Medical Center uses the most advanced healthcare technologies, including pioneering surgical systems like – ExactechGPS® and ExcelsiusGPS®. Recognized among the top 3% of all California acute care hospitals, Long Beach Medical Center is recognized as "Best Hospital" for OBGYN and Orthopedics and ranked regionally in the Los Angeles Metro Area by U.S. News & World Report and earned Magnet® recognition for nursing excellence. With premier centers dedicated to cancer, heart, rehabilitation, orthopedics, neurosciences, and trauma, physicians and surrounding hospitals continually refer to its accredited programs. For more information, visit View original content to download multimedia: SOURCE MemorialCare Long Beach Medical Center